Open AccessIMMUNOLOGICAL ALTERNATION OF LEUKEMIC CELLS In Vivo AFTER TREATMENT WITH AN ANTITUMOR DRUG
Author(s) -
Enzo Bonmassar,
Anna Bonmassar,
S Vadlamudi,
Abraham Goldin
Publication year - 1970
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.66.4.1089
Subject(s) - in vivo , drug , alternation (linguistics) , leukemia , biology , pharmacology , cancer research , immunology , medicine , chemistry , genetics , philosophy , linguistics
L1210 leukemia was transplanted serially in CDF1 mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DIC, NSC 45388). After four different lines (C lines) had been treated for several generations, a marked increase in survival time of untreated mice was observed. In contrast, mice treated with DIC or immunosuppressed with cyclophosphamide succumbed earlier with generalized leukemia. Furthermore, a C line showed unusually high sensitivity to chemotherapeutic treatment with 1,3 bis(2-chloroethyl)-1-nitrosourea. The data suggest that C lines acquired strong antigenicity for CDF1 and DBA/2 hosts. DIC treatment may have selected highly antigenic variants or induced somatic mutations resulting in the appearance of strong new transplantation antigen(s).